Cost–benefit analysis of first‐trimester pre‐eclampsia screening: comparison of multivariable <scp>Gaussian</scp> algorithm with and without placental growth factor
Although the Gaussian algorithm without PlGF demonstrated the highest cost savings compared with no screening, incorporating PlGF further improved PE prevention, supporting its broader adoption. A PlGF reagent cost per unit below €4.31 may make this strategy cost-beneficial, enhancing its clinical implementation. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
Authors
- Nerea Maíz (ORCID: https://orcid.org/0000-0001-8261-6383)
- Erika Bonacina (ORCID: https://orcid.org/0000-0002-8042-8247)
- Mireia Armengol‐Alsina (ORCID: https://orcid.org/0000-0002-2087-5176)
- Joaquín Temprado (ORCID: https://orcid.org/0009-0002-3898-0203)
- Alba Casellas (ORCID: https://orcid.org/0009-0008-9135-4221)
- A. Arias
- M. Dalmau
- E. Del Barco
- M. Mendoza
- R. Ferrer‐Costa
- E. Roldán (ORCID: https://orcid.org/0009-0003-8109-8985)
Institutions
- Universitat Autònoma de Barcelona (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Vall d'Hebron Hospital Universitari (ES)
Publication Details
- Journal
- Ultrasound in Obstetrics and Gynecology
- Published
- 2026-01-03
- DOI
- https://doi.org/10.1002/uog.70155
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Instituto de Salud Carlos III